Dr Michael KC Lee will discuss how genomic techniques are being utilised to understand the effects of PRMT5 inhibition and how genomic research then translates into clinical trials.
Dr Jia (Jenny) Liu will share experiences with MAT2A inhibitors and PRMT5 inhibitors used in clinical trials for MTAP-deleted solid tumors, as a novel synthetic lethal target.
This hybrid event is part of the VCCC Alliance Precision Oncology Forum series. These multi-disciplinary forums provide opportunities to discuss new research topics in Precision Oncology, as well as interesting and novel cases illustrating the clinical implications of molecular pathology and targeted therapies.
Cases are discussed on an individual, de-identified basis.
Dr Lee is a medical oncologist with an interest in pancreatic genomic research stemming from his fellowship at BC Cancer, Vancouver. He returned to Melbourne and undertook a PhD to bridge the knowledge gap between wet lab scientists and bioinformaticians in driving effective translational research in developing novel therapies that were desperately needed for patients with pancreatic cancer.
Dr Lee is honoured to have received support from the University of Melbourne Clinical Pathology Scholarship, RACP Research Entry Scholarship and Pancare Foundation grant for his ongoing PhD research. He is the inaugural recipient of the Paul Dear Post Doctoral Researcher Scholarship for his work beyond his PhD, focusing on PRMT5 inhibitors. Clinically, he sub-specialises in patients with neuroendocrine and upper GI cancers at the Peter Mac and contributes toward the molecular tumour board both at the VCCC and MPCCC.
Dr Liu is a medical oncologist specialising in drug development and early phase clinical trials, as well as head and neck cancer at The Kinghorn Cancer Centre, St Vincent’s Hospital, Sydney. She cares for patients with advanced, often treatment-fractory cancer, who lack standard of care options, and enrols patients on clinical trials of novel therapies.
Dr Liu is passionate about patient-centred care, and conducts an extensive portfolio of research examining biomarkers to improve treatment outcomes for patients, and supportive care/psychological needs of cancer patients on treatment. She collaborates extensively with research institutes, national and international clinical trials consortia including NECTA (NSW Early Phase Trials Alliance), Worldwide Innovative Network (WIN) and Melanoma and Skin Cancer Cooperative Group (MASC) to bring novel therapies to patients in need in Australia.
Content warning: The VCCC Alliance Precision Oncology Forum is aimed primarily at a clinical audience and features open discussion about real cases and patients. While these cases are de-identified, the imagery, content and discussion can be graphic.
